American Association for the Advancement of Science
Up to 30 percent of patients with B cell malignancies such as lymphoma relapse after CAR T cell treatment, partly because their lymphoma cells stop expressing the target antigen
According to a recent review, the three drugs may be underused in part because access is limited by some legal requirements regarding who can write prescriptions
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.